Medifast (MED) stock plunges on earnings miss, weak outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Medifast (MED) PT Lowered to $25 at DA Davidson
April 30, 2024 5:00 AM EDTDA Davidson analyst Linda Bolton Weiser lowered the price target on Medifast (NYSE: MED) to $25.00 (from $40.00) while maintaining a Neutral rating.
The analyst comments "NEUTRAL-rated MED reported a small 1Q24 sales beat but profit missed consensus by 11% due to higher SG&A... More
Medifast (MED) Misses Q1 EPS by 84c, Guidance Misses
April 29, 2024 4:10 PM EDTMedifast (NYSE: MED) reported Q1 EPS of $0.66, $0.84 worse than the analyst estimate of $1.50. Revenue for the quarter came in at $174.7 million versus the consensus estimate of $205.79 million.
GUIDANCE:
Medifast sees Q2 2024 EPS of $0.05-$0.40, versus the consensus of $0.67. Medifast sees Q2... More
